Arcutis Biotherapeutics (ARQT) vs Zai Lab (ZLAB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Arcutis Biotherapeutics (ARQT) has outperformed Zai Lab (ZLAB) over the past year, gaining 17.5% versus a loss of 23.0%. Over five years, ARQT leads with a +8.5% price change compared with -75.2% for ZLAB. Arcutis Biotherapeutics is the larger company by market cap ($3.03 billion vs $2.78 billion), about 1.1 times the size.
Arcutis Biotherapeutics converts more of its revenue into profit, with a net margin of -4.3% versus -38.1%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARQT | ZLAB |
|---|---|---|
| Share price | $24.14 | $24.73 |
| Market cap | $3.03B | $2.78B |
| 1-day change | -0.12% | -2.29% |
| YTD return | -16.77% | +43.48% |
| 1-year return | +17.50% | -23.05% |
| 5-year return | +8.48% | -75.19% |
| P/E ratio (TTM) | 109.73 | — |
| Forward P/E | 17.75 | — |
| EPS (TTM) | $0.22 | $-1.70 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $376.07M | $460.16M |
| Revenue growth (YoY) | +91.34% | +15.33% |
| Net income (latest FY) | $-16.14M | $-175.54M |
| Gross margin | 90.24% | 58.60% |
| Operating margin | -3.25% | -49.86% |
| Net margin | -4.29% | -38.15% |
| 52-week high | $31.77 | $33.65 |
| 52-week low | $19.30 | $15.96 |
| Distance from 52-week high | -24.02% | -26.51% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +53.27% | +34.01% |
| Average volume | 2.22M | 944.83K |
| Shares outstanding | 125.69M | 112.27M |
| Employees | 354 | 1,784 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ARQT has outperformed ZLAB by 40.5 percentage points over the past year.
- Arcutis Biotherapeutics is more profitable, keeping -4.3 cents of every revenue dollar as net income versus -38.1 cents for Zai Lab.
- Arcutis Biotherapeutics grew revenue faster in its latest fiscal year (+91.34% vs +15.33%).
About Arcutis Biotherapeutics
ARQT stock →Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 354 employees
About Zai Lab
ZLAB stock →Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,784 employees
ARQT vs ZLAB FAQ
Which is bigger, Arcutis Biotherapeutics or Zai Lab?
Arcutis Biotherapeutics (ARQT) is larger, with a market capitalization of $3.03B compared with $2.78B for Zai Lab (ZLAB).
Which stock has performed better over the past year, ARQT or ZLAB?
ARQT returned +17.50% over the past 12 months, compared with -23.05% for ZLAB (price return, excluding dividends). Past performance does not predict future results.
Are Arcutis Biotherapeutics and Zai Lab in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.